Table 1 Baseline characteristics of study participants for scRNA-seq and snRNAseq
Patients | P1 | P2 | P3 | P4 | P5 | P6 | P7 | P8 | P9 |
|---|---|---|---|---|---|---|---|---|---|
Sample no | LA6 (cell) | LA7 (cell) | LA8 (cell) | LA9 (cell) | LA10 (cell) | LA11 (cell) | LA12 (cell) | LA13 (cell) | LA3or4 (nuclei) |
Nuclei or Cell | Â | LA1or2 (nuclei) | LA1or2 (nuclei) | Â | LA5 (nuclei) | LA3or4 (nuclei) | Â | Â | Â |
Characteristics | |||||||||
AF duration (months) | 6 | 13 | 9 | 120 | 240 | 360 | 240 | 120 | 120 |
Age | 41 | 64 | 76 | 75 | 79 | 70 | 72 | 62 | 80 |
Sex | F | M | F | M | M | M | M | M | M |
BMI (kg/m2) | 27.1 | 22.5 | 24.3 | 29.8 | 24 | 25.2 | 20.8 | 26.1 | 25.9 |
History of smoking | − | + | − | + | + | + | − | + | − |
Stroke | − | + | + | + | + | + | − | − | + |
Bleeding | − | + | + | − | + | − | − | − | + |
Hypertension | − | + | + | + | + | + | + | − | + |
Diabetes | − | + | + | + | − | − | − | − | − |
Dyslipidemia | − | − | + | + | − | − | + | + | − |
Medications | |||||||||
Anticoagulant | Dab | War | Api | Riv | Api | Dab | Edo | Riv | Edo |
Antiplatelet drug | − | − | + | − | − | − | − | + | − |
Antiarrhythmia drug | − | − | − | − | − | − | + | − | + |
β-blocker | + | + | + | − | + | + | − | + | + |
Ca blocker | − | − | + | + | + | + | + | + | − |
Echocardiogram | |||||||||
LVEF (%) | 47 | 50 | 65 | 37 | 61 | 65 | 68 | 34 | 44 |
LA diameter (mm) | 44 | 51 | 44 | 58 | 59 | 63 | 56 | 52 | 59 |
